0001641489-24-000045.txt : 20240614 0001641489-24-000045.hdr.sgml : 20240614 20240614162216 ACCESSION NUMBER: 0001641489-24-000045 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240611 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20240614 DATE AS OF CHANGE: 20240614 FILER: COMPANY DATA: COMPANY CONFORMED NAME: vTv Therapeutics Inc. CENTRAL INDEX KEY: 0001641489 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 473916571 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37524 FILM NUMBER: 241045164 BUSINESS ADDRESS: STREET 1: 3980 PREMIER DR STREET 2: SUITE 310 CITY: HIGH POINT STATE: NC ZIP: 27265 BUSINESS PHONE: 336-841-0300 MAIL ADDRESS: STREET 1: 3980 PREMIER DR STREET 2: SUITE 310 CITY: HIGH POINT STATE: NC ZIP: 27265 FORMER COMPANY: FORMER CONFORMED NAME: VTV Therapeutics Inc. DATE OF NAME CHANGE: 20150506 8-K 1 vtvt-20240611.htm 8-K vtvt-20240611
FALSE0001641489NASDAQ00016414892024-06-112024-06-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported):  June 11, 2024
vTv Therapeutics Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-37524
47-3916571
(State or other jurisdiction
of incorporation)
(Commission File No.)
(IRS Employer
Identification No.)
3980 Premier Drive, Suite 310
High Point, NC 27265
(Address of principal executive offices)
(336) 841-0300
(Registrant’s telephone number, including area code)
NOT APPLICABLE
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A common stock, par value $0.01 per shareVTVT
NASDAQ Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨



Item 5.07    Submission of Matters to a Vote of Security Holders.
On June 11, 2024, vTv Therapeutics Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below:

(1)Based on the following results of the voting, the Company’s stockholders elected the nominees listed below to the Company’s Board of Directors, each to serve for a term to expire at the Company’s 2025 annual meeting of stockholders or until their successors are duly elected and qualified:

Director Nominee
For
Withheld
Broker Non Votes
Srinivas Akkaraju
1,912,870
7,825
294,269
Raymond Cheong
1,913,019
7,676
294,269
Fahed Al Marzooqi
1,887,098
33,597
294,269
Richard S. Nelson
1,913,112
7,583
294,269
Anne Phillips
1,913,111
7,584
294,269
Paul Sekhri
1,913,689
7,006
294,269
Daniel K. Spiegelman
1,913,127
7,568
294,269
(2)The Company’s stockholders approved the adoption of the 2024 Equity Incentive Plan based upon the following results of the voting:

For
AgainstAbstainBroker Non Votes

1,814,842
103,928
1,925
294,269
(3)The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified based on the following results of the voting:

For
AgainstAbstainBroker Non Votes

2,106,193
9,580
99,191
0


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
VTV THERAPEUTICS INC.
By:/s/ Paul J. Sekhri
Name:Paul J. Sekhri
Title:
Chairman, President, and Chief Executive Officer
Dated: June 14, 2024

 EX-101.SCH 2 vtvt-20240611.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 vtvt-20240611_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, State or Province Entity Address, State or Province Security Exchange Name Security Exchange Name Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Postal Zip Code Entity Address, Postal Zip Code Cover [Abstract] Written Communications Written Communications Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security City Area Code City Area Code Document Period End Date Document Period End Date Amendment Flag Amendment Flag Entity Tax Identification Number Entity Tax Identification Number Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Pre-commencement Tender Offer Pre-commencement Tender Offer Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 vtvt-20240611_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
Jun. 11, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jun. 11, 2024
Entity Registrant Name vTv Therapeutics Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-37524
Entity Tax Identification Number 47-3916571
Entity Address, Address Line One 3980 Premier Drive, Suite 310
Entity Address, City or Town High Point
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27265
City Area Code 336
Local Phone Number 841-0300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A common stock, par value $0.01 per share
Trading Symbol VTVT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001641489
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://vtvtherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - vtvt-20240611.htm 4 vtvt-20240611.htm vtvt-20240611.xsd vtvt-20240611_lab.xml vtvt-20240611_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "vtvt-20240611.htm": { "nsprefix": "vtvt", "nsuri": "http://vtvtherapeutics.com/20240611", "dts": { "inline": { "local": [ "vtvt-20240611.htm" ] }, "schema": { "local": [ "vtvt-20240611.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd" ] }, "labelLink": { "local": [ "vtvt-20240611_lab.xml" ] }, "presentationLink": { "local": [ "vtvt-20240611_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2024": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://vtvtherapeutics.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240611.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20240611.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001641489-24-000045-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001641489-24-000045-xbrl.zip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end XML 17 vtvt-20240611_htm.xml IDEA: XBRL DOCUMENT 0001641489 2024-06-11 2024-06-11 false 0001641489 NASDAQ 8-K 2024-06-11 vTv Therapeutics Inc. DE 001-37524 47-3916571 3980 Premier Drive, Suite 310 High Point NC 27265 336 841-0300 false false false false Class A common stock, par value $0.01 per share VTVT NASDAQ false